Online inquiry

IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4342MR)

This product GTTS-WQ4342MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL5RA gene. The antibody can be applied in Chronic Obstructive Pulmonary Disease (COPD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000564.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3568
UniProt ID Q01344
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4342MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14766MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ13481MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ14872MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ10998MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ14392MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ11038MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ1583MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-083
GTTS-WQ3697MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 2287409
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW